Latest news

Takeda, Zinfandel ax Alzheimer’s test for pioglitazone, chalking up another AD fail

By Ben Adams
1/25/18
 
Japanese Big Pharma Takeda and U.S. partner Zinfandel Pharmaceuticals have decided to give up and stop testing a 20-year-old diabetes medicine that they hoped could work as a new Alzheimer’s therapy.  
 
The details from the brief update: The so-called "Tomorrow" trial has been pulled after the pair got their hands on a planned interim futility analysis, which showed that Actos (pioglitazone), already approved as a diabetes medicine (and as a generic), had an “an inadequate treatment effect […] in delaying the onset of mild cognitive impairment due to Alzheimer’s disease.”
 
Read: It didn’t work, although they added it had no safety issues.
 
Read more.